期刊
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH
卷 13, 期 4, 页码 526-544出版社
KOREAN ACAD ASTHMA ALLERGY & CLINICAL IMMUNOLOGY
DOI: 10.4168/aair.2021.13.4.526
关键词
COVID-19; vaccine; anaphylaxis; pandemics; public health; immunization; immunity; hypersensitivity; preservatives
In the era of the novel coronavirus epidemics, COVID-19 vaccines have been recognized as one of the most effective public health interventions to control the pandemic. However, severe allergic reactions can occur after vaccinations, with potential allergenic/immunogenic excipients such as PEG and polysorbate 80 in COVID-19 vaccines. Contraindications to vaccination include a history of severe allergic reactions to the vaccine or proven hypersensitivity to a vaccine component.
In the era of novel coronavirus epidemics, vaccines against coronavirus disease 2019 (COVID-19) have been recognized as the most effective public health interventions to control the pandemic. An adverse event following immunization (AEFI) is defined as any untoward occurrence following immunization, and the majority of AEFIs are caused by protective immune responses stimulated by vaccines. Most of the reported AEFIs are not serious, and many are not immunologically mediated or even reproducible on re-exposure. However, uncommon severe allergic adverse reactions, such as anaphylaxis or other allergic reactions, can occur after vaccinations. Confirmed allergic reactions to vaccines may be caused by residual non-human protein, preservatives, or stabilizers in the vaccine formulation (also known as excipients). There are 2 main potential allergenic/immunogenic excipients in COVID-19 vaccines, polyethylene glycol (PEG) and polysorbate 80. PEG, also known as macrogol, is an ingredient in various laxatives and injectable formulations, such as depot steroids. Polysorbate 80 is present in various medical products, creams, ointments, lotions, and medication tablets. Contraindications to the administration of COVID-19 vaccines include a previous history of severe allergic reactions to the first dose of COVID-19 vaccine or proven hypersensitivity to a vaccine component, such as PEG or polysorbate 80. Anaphylaxis or other allergic reactions following immunization can cause fear and loss of confidence in the safety of vaccines among the public. A better understanding of these events is thought to help alleviate concerns about the current COVID-19 vaccines and provide reassurance to the general population by analyzing the exact incidence of anaphylaxis and potential risk factors. COVID-19 vaccine-associated anaphylaxis could be prevented and managed by risk stratification based on our local and global experience.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据